Clene (NASDAQ: CLNN)
$0.35
(5.8%)
$0.02
Price as of April 19, 2024, 4:00 p.m. ET
Clene Return vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
Clene Company Info
Clene, Inc. is a clinical-stage biopharmaceutical company, which focuses on the development of therapeutics for neurodegenerative diseases. It offers a nanotechnology drug platform for the development of a new class of orally administered neurotherapeutic drugs. The company was founded on August 12, 2020 and is headquartered in Salt Lake City, UT.
News & Analysis
Featured Article
Why Shares of Clene Jumped 11.8% on Monday
The company's lead therapy has shown progress against ALS in preliminary trials.
Jim Halley | Jul 18, 2022
Featured Article
Why Clene Stock Skyrocketed Today
One Wall Street analyst has high hopes for the biopharmaceutical company.
Prosper Junior Bakiny | Feb 3, 2021
Valuation
Related Stocks
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.